Study of ITP patients after spleen removal
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at how people with immune thrombocytopenia (ITP) are doing after having their spleen removed. By tracking your health over time, researchers hope to learn more about the long-term results of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have primary immune thrombocytopenia (ITP).
- You had your spleen removed (splenectomy) between January 1, 2010 and December 31, 2022.
- You agree to take part in the study by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
This study tests a combination of three treatments—steroids, IVIG, and romiplostim (Nplate)—for adults with severe, newly diagnosed ITP that hasn't responded well to standard therapy. The goal is to see if this triple therapy can quickly raise platelet counts and stop bleeding.
This study checks how your immune system is doing before and after a spleen removal surgery (splenectomy) for immune thrombocytopenia (ITP). It may help doctors better understand what changes happen in the body and how to improve care for people with ITP.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.